Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 699 Breast Neoplasms 630 Neoplasms 582 Leukemia, Myeloid, Acute 481 Colorectal Neoplasms 456 Multiple Myeloma 444 Melanoma 426 Prostatic Neoplasms 383 Neoplasm Metastasis 373 Pancreatic Neoplasms 363 Recurrence 350 Lymphoma 340 Ovarian Neoplasms 325 Lung Neoplasms 297 Lymphoma, Non-Hodgkin 295 Leukemia 287 Glioblastoma 275 Precursor Cell Lymphoblastic Leukemia-Lymphoma 249 Stomach Neoplasms 246 Leukemia, Lymphocytic, Chronic, B-Cell 235 Carcinoma, Hepatocellular 231 Squamous Cell Carcinoma of Head and Neck 220 Lymphoma, Large B-Cell, Diffuse 217 Myelodysplastic Syndromes 212 Carcinoma, Renal Cell 210 Lymphoma, Follicular 183 Head and Neck Neoplasms 172 Brain Neoplasms 169 Lymphoma, Mantle-Cell 167 Triple Negative Breast Neoplasms 166

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Anal Cancer Metastatic × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡